Skip to content

    Vinati Organics

    VINATIORGA
    Chemicals·27 May 2026
    Management Summary

    Vinati Organics reported a resilient Q4 and FY26, with consolidated EBITDA growing 13% and PAT 9% for the full year. The company successfully completed ATBS capacity expansion and targets 15% overall volume growth for FY27. Despite challenges like IBB raw material issues and delays in VOPL's new product commercialization, the company remains debt-free and maintains a strong capex pipeline for future growth.

    Highlights

    5
    • Consolidated EBITDA for FY26 grew by 13% to INR707 crores from INR625 crores in FY25.

    • Consolidated PAT for FY26 increased by 9% to INR444 crores from INR405 crores in FY25.

    • Q4 FY26 consolidated EBITDA grew 15% QoQ to INR191 crores, and PAT grew 23% QoQ to INR123 crores.

    • ATBS capacity expansion successfully completed, and the company expects 15% volume growth in ATBS for the next 3 years.

    • Company remains debt-free with a treasury of INR190 crores as of March 31, 2026.

    Concerns

    3
    • IBB volume declined by approximately 20% in FY26 compared to FY25 due to raw material unavailability from the Iran war, though now resolved.

    • Antioxidants ADD application was initially rejected, and despite reapplying, a decision is expected to take another 6-9 months, impacting the ability to counter aggressive selling by Chinese competitors.

    • VOPL subsidiary's new products faced teething troubles and require process re-engineering, delaying revenue contribution until Q3 FY27.

    Key financials

    Metrics

    6

    Periods

    2

    Q4 FY26

    3
    • Consolidated Net Income
      ₹624 Cr
      QoQ+15.6%
    • Consolidated EBITDA
      ₹191 Cr
      QoQ+15.8%
    • Consolidated PAT
      ₹123 Cr
      QoQ+21.8%

    FY26

    3
    • Consolidated Net Income
      ₹2,280 Cr
      YoY0%
    • Consolidated EBITDA
      ₹707 Cr
      YoY+13.1%
    • Consolidated PAT
      ₹444 Cr
      YoY+9.6%

    Segment breakdown

    ATBS
    33% Revenue Contribution
    Antioxidants (AO)
    17.5% Revenue Contribution
    IB
    11% Revenue Contribution
    IBB
    11% Revenue Contribution
    Customized and Other Products
    Revenue Contribution
    List

    Capital allocation

    4
    high confidence
    CategoryHeadline
    Capex

    ₹200 crores

    internal accruals

    Debt

    Gross ₹0 crores · Net ₹-190 crores

    Dividend

    ₹8.5/share (final)

    Liquidity

    Cash ₹190 crores

    Company has a treasury of INR190 crores as on 31st March 2026.

    Guidance & targets

    12
    CategoryTargetPriority
    Volume
    Overall Company Volume Growth
    15%
    High
    Volume
    ATBS Volume Growth
    15%
    High
    Volume
    Butyl Phenols Growth
    moderate growth
    Medium
    Volume
    IB and HP-MTBE Growth
    double-digit growth
    High
    Revenue
    Antioxidants Segment Momentum
    strong momentum
    Medium
    Revenue
    VOPL Revenue Contribution
    from Q3 FY27 onwards
    High
    Revenue
    VOPL Revenue (FY27)
    INR100-120 crores
    High
    Revenue
    MEHQ/Guaiacol Project Revenue (FY27)
    INR100 crores
    High
    Revenue
    Antioxidants Revenue Scale
    INR800-900 crores
    High
    Capex
    Capex for FY27
    INR200-250 crores
    High
    Capex
    Annual Capex
    INR250-300 crores
    High
    Profitability
    EBITDA Margin
    26-27%
    High

    VOPL Process Re-engineering Completion

    by September 2026
    CurrentUnder re-engineering
    TargetCompleted, production started

    Why it matters

    Successful completion is crucial for VOPL to start contributing revenue from Q3 FY27 as planned.

    Under VOPL, a 100% subsidiary of VOL, a few products require process reengineering, which is expected to take approximately 6 months with revenue contribution anticipated from Q3 of FY27 onwards. So the plant is presently under reengineering. And hence, it should be done by September, and we expect production from October and sales so on and so forth.

    How to verify

    detailed_narrative

    Risks & concerns

    5
    RiskSeverity

    IBB Raw Material Supply Disruption

    IBB volume declined by 20% in FY25 due to unavailability of key raw materials from the Iran war, but this constraint has now been allied and production is back on track.Management acknowledged

    low

    ATBS Demand Softness in Non-US Markets

    Volume demand in non-U.S. markets was slow or low, but the company has witnessed a recovery and expects 15-20% volume growth in FY27.Management acknowledged

    medium

    VOPL New Product Commercialization Delays

    VOPL's new products faced teething troubles and require process re-engineering, delaying revenue contribution until Q3 FY27.Management acknowledged

    medium

    China Overcapacity and Dumping in Antioxidants

    The ADD application for antioxidants was rejected, and Chinese competitors are undercutting and selling aggressively, impacting the segment. A reapplication is pending a 6-9 month decision.Management acknowledged

    high

    Sectoral Cyclicality and Market Volatility

    The sector has experienced shorter cycles, overstocking, and fluctuations in raw material and logistics costs, but the company claims to have managed these well by passing on price changes.Management acknowledged

    medium

    Q&A highlights

    6

    “So some of the projects -- products that are under implementation, most of them are downstream processes as in downstream integration for our products, value-added products. They will be catering to segments such as the fragrance industry, such as personal care, antioxidants in the food additives business. But most of them, I think what's important, they are niche chemicals. We are targeting niche chemicals going forward. Some are also in the plastics segment. In this current financial year '26-'27, you can expect 2 or 3 products are in our pipeline, and it is expected to come in the second half of this financial year. Yes. So revenues in '28, you're right.”

    Clarifies the nature of new products (niche, value-added, downstream integration) and provides a timeline for their commercialization and revenue contribution (H2 FY27 for launch, FY28 for revenues).

    asked by Rohit Nagraj

    3 min read6 chapters

    Detailed Narrative

    01

    Q4 and Full Year FY26 Financial Performance

    Vinati Organics reported a robust Q4 FY26, with consolidated net income increasing by 16% QoQ to INR624 crores and EBITDA growing 15% QoQ to INR191 crores. Consolidated PAT for the quarter saw a strong 23% QoQ growth, reaching INR123 crores. For the full fiscal year FY26, consolidated net income remained stable at INR2,280 crores, while EBITDA grew 13% to INR707 crores from INR625 crores in FY25. PAT for FY26 increased by 9% to INR444 crores compared to INR405 crores in the previous year, demonstrating resilient performance despite market challenges🌐.

    02

    Segmental Performance and FY27 Outlook

    The company's ATBS segment maintained a robust global market share, with capacity expansion successfully completed, and expects 15% volume growth for the next three years. The butyl phenols segment delivered steady performance in FY26 and anticipates moderate growth in FY27. IB and HP-MTBE are projected to achieve double-digit growth in FY27. The customized products segment recorded strong 10% YoY growth, while the antioxidants business grew 15% in FY26 and is expected to maintain strong momentum in FY27. Overall, Vinati Organics targets approximately 15% volume growth at the company level for FY27.

    03

    Capital Expenditure and Future Growth Initiatives

    In FY26, Vinati Organics incurred INR270 crores in capex, primarily for VOPL, capacity expansion, and new product development. For FY27, the company has earmarked INR200-250 crores for continued investment in capacity expansion, innovation, and operational efficiency. The company plans to invest INR250-300 crores annually for the next 3-5 years, focusing on value-added products from existing lines for industries like fragrance, personal care, food additives, and plastics. The ATBS capacity expansion, involving two phases, cost between INR250-300 crores.

    04

    VOPL Subsidiary Update and Re-engineering

    The 100% subsidiary, VOPL, contributed minimally with only INR10 crores in sales in FY26. The new products at VOPL faced initial teething troubles and require process re-engineering, which is expected to be completed by September 2026. Production is anticipated to commence from October 2026, with revenue contribution expected from Q3 FY27 onwards. Management projects VOPL to generate INR100-120 crores in revenue in FY27 after the re-engineering is done, with the MEHQ/Guaiacol project being a primary contributor to this target.

    05

    Raw Material Stability and Market Headwinds

    The company experienced a 20% volume decline in IBB in FY25 due to raw material unavailability linked to the Iran war, but these issues have since been resolved, and production is back on track. While the sector has faced cyclicality, overstocking, and fluctuations in raw material and logistics costs, Vinati Organics states it has managed these headwinds effectively. The company has maintained its margins by passing on price increases and decreases, ensuring stability in its operations.

    06

    Antioxidants Business and Anti-Dumping Duty (ADD)

    The antioxidants business delivered 15% revenue growth in FY26, but continues to face challenges from aggressive undercutting and selling by Chinese competitors. The company's application for Anti-Dumping Duty (ADD) on antioxidants was initially rejected. Vinati Organics has reapplied, citing a strong case, but expects a decision to take another 6 to 9 months. This ongoing situation highlights the competitive pressure in the segment, which management aims to address through regulatory support.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.